{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-24-006533","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.501920+00:00","generated_at":"2026-05-31T00:44:08.097347+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Zeo ScientifiX partners with Physicians Group for Phase 2 clinical trials","bullets":["Physicians Group operates 75 clinics and 750+ clinicians, treating 1,500-2,000 patients monthly.","Collaboration targets Phase 2 trials of Zofin™ for several indications and other pipeline products.","Zeo completed Phase 1 for Zofin; aims for FDA approval for various diseases and chronic conditions.","Regenerative medicine market projected to reach ~$175B by 2032 with 22.8% CAGR per Precedence Research."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-24-006533","json":"https://secwatch.observer/filing/0001829126-24-006533.json","markdown":"https://secwatch.observer/filing/0001829126-24-006533.md","text":"https://secwatch.observer/filing/0001829126-24-006533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912624006533/0001829126-24-006533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912624006533/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:44:08.097347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}